Below is an educational, technical answer to a question many patients and clinicians ask. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ.
How long is recovery after tumor ablation?
Because percutaneous ablation is minimally invasive, many patients are described as recovering relatively quickly compared with open surgery, though this varies by case. A short observation period and follow-up imaging to assess the treated zone are commonly part of aftercare. The extent of the tumor, its location, and the patient's overall condition all influence the recovery timeline. Specific activity and follow-up guidance is set by the treating clinician for each patient.
What This Means in Practice
Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes. For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning. Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
Key Considerations
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning.
- All INVAMED ablation devices are intended for use by trained clinicians under appropriate image guidance and in accordance with the IFU.
Frequently Asked Questions
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Wavelength, fiber type, and power settings influence the balance between vaporization and coagulation, and are selected according to the instrument system and clinical goal. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. Patient selection, the chemotherapy regimen, and the treatment schedule are determined by the treating oncology and urology team. Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes. Image guidance, applicator trajectory, and the decision to treat percutaneously versus by another route remain clinical judgments made by the operator. INVAMED's Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors is positioned specifically for intraosseous RF delivery in vertebral and spinal tumor ablation. Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. Whether intraosseous ablation is appropriate, and how it fits within a broader oncologic and pain-management plan, is determined by the clinician.
Related on INVAMED
- Oncology Ablation — product category
- What is the success rate of liver tumor ablation?
- What size tumor can be ablated (the 3 cm rule)?
- Microwave Ablation (MWA) Systems Explained — A Technical Guide
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.